CCN(C(C)C)C(C)C.[C:10]1([C:16]2[NH:20][N:19]=[C:18]([C:21]([NH:23][CH2:24][C:25]([OH:27])=O)=[O:22])[CH:17]=2)[CH:15]=[CH:14][CH:13]=[CH:12][CH:11]=1.C1C=CC2N(O)N=NC=2C=1.CCN=C=NCCCN(C)C.Cl.[F:50][C:51]1[CH:62]=[CH:61][C:60]([F:63])=[CH:59][C:52]=1[O:53][CH:54]1[CH2:58][CH2:57][NH:56][CH2:55]1>CN(C=O)C.O>[F:50][C:51]1[CH:62]=[CH:61][C:60]([F:63])=[CH:59][C:52]=1[O:53][CH:54]1[CH2:58][CH2:57][N:56]([C:25](=[O:27])[CH2:24][NH:23][C:21]([C:18]2[CH:17]=[C:16]([C:10]3[CH:11]=[CH:12][CH:13]=[CH:14][CH:15]=3)[NH:20][N:19]=2)=[O:22])[CH2:55]1DIPEA (166 mg, 1.28 mmol) was added to a stirred solution of [(5-phenyl-1H-pyrazole-3-carbonyl)-amino]-acetic acid (70 mg, 0.28 mmol) in DMF (5 mL) followed by HOBt (42 mg, 0.31 mmol) and EDCI (136 mg, 0.71 mmol). After 2 minutes of stirring, 3-(2,5-difluoro-phenoxy)-pyrrolidine hydrochloride (prepared by the method used for the synthesis of Intermediate 72) (74 mg, 0.3 mmol) was added and the resulting mixture was stirred at room temperature overnight. Cold water was added and the precipitate was collected. The solid was purified by recrystallisation from a mixture of 20% ethyl acetate in hexane (15 mL), water (0.5 mL) and MeOH (0.03 mL) to afford 92 mg (76% Yield) of 5-phenyl-1H-pyrazole-3-carboxylic acid {2-[3-(2,5-difluoro-phenoxy)-pyrrolidin-1-yl]-2-oxo-ethyl}-amide. LC/MS [M+H]+: 427.15. 1H NMR (300 MHz, DMSO-d6): δ 13.8 (s, 1H), 8.1 (s, 1H), 7.84 (d, 2H), 7.54-7.12 (m, 6H), 7.14 (s, 1H), 6.88 (t, 1H), 5.3 (d, 1H), 4.1 (d, 2H), 3.9-3.5 (m, 4H), 2.3 (s, 1H), 2.1 (s, 1H).